PCOS Emerging Research and Trials to Watch in 2026

The 2023 International PCOS Guideline: What Changed

The 2023 update to the International Evidence-Based Guideline for the Assessment and Management of PCOS, endorsed by over 40 societies worldwide, introduced several major shifts in clinical practice. The guideline formally recommended anti-Müllerian hormone (AMH) as a diagnostic alternative to pelvic ultrasound in adult women, acknowledged the role of emotional wellbeing screening, and placed greater emphasis on lifestyle intervention as first-line therapy [1].

One of the most significant changes involved diagnostic thresholds. The guideline raised the follicle count threshold for polycystic ovarian morphology from 12 to 20 follicles per ovary when using modern high-resolution ultrasound, reflecting improved imaging technology that was detecting more follicles in healthy women and producing false positives [1]. This single change reclassified a meaningful number of borderline cases.

The updated guideline also recommended that clinicians screen all women with PCOS for metabolic risk factors including type 2 diabetes, dyslipidemia, and cardiovascular risk, regardless of BMI. This was a departure from older practice patterns that focused metabolic screening primarily on women with obesity. As the guideline authors noted, "insulin resistance is present in the majority of women with PCOS across the weight spectrum" [1]. The Endocrine Society's earlier 2013 clinical practice guideline had already flagged this issue, but the 2023 update made the recommendation more explicit and actionable [2].

For mental health, the guideline introduced a formal recommendation to screen for anxiety, depression, eating disorders, and psychosexual dysfunction at diagnosis and during follow-up. Prior editions mentioned psychological wellbeing but stopped short of structured screening protocols [1].

GLP-1 Receptor Agonists: The Most Watched Drug Class in PCOS

GLP-1 receptor agonists represent the single most active area of pharmacological research in PCOS right now. Liraglutide was the first GLP-1 RA studied in this population, and a 2017 randomized controlled trial (N=72) comparing liraglutide 1.8 mg daily to metformin in overweight women with PCOS found that liraglutide produced greater weight loss (5.6 kg vs. 3.8 kg at 12 weeks) and comparable improvements in menstrual cyclicity [3].

Semaglutide has generated even more interest. A 2023 systematic review and meta-analysis published in Frontiers in Endocrinology pooled data from trials of GLP-1 RAs in PCOS and found significant reductions in BMI, fasting insulin, HOMA-IR, and total testosterone compared to placebo or metformin [4]. The weight loss data from the broader STEP trial program (not PCOS-specific) showed 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961), establishing the magnitude of effect that researchers hope to replicate in PCOS-specific populations [5].

Tirzepatide, the dual GIP/GLP-1 receptor agonist, achieved 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) in participants with obesity [6]. Its dual mechanism and superior weight loss results have prompted active investigation in PCOS. Multiple registered trials on ClinicalTrials.gov are now evaluating tirzepatide's effects on ovulation, androgen levels, and metabolic parameters in women with PCOS. The hypothesis is that the pronounced insulin-sensitizing effect of dual incretin agonism may address the root pathophysiology of PCOS more effectively than GLP-1 agonism alone.

A critical question that these trials aim to answer: do GLP-1 RAs improve PCOS outcomes through weight loss alone, or do they exert direct effects on ovarian function and androgen production independent of weight change? Preclinical data suggest GLP-1 receptors are expressed in ovarian tissue, raising the possibility of direct gonadal effects [4]. If confirmed, this would change how clinicians think about these drugs in normal-weight women with PCOS who have insulin resistance but do not need weight loss.

Anti-Müllerian Hormone as a Diagnostic Tool

AMH measurement is positioned to change how PCOS is diagnosed. Women with PCOS typically have AMH levels two to four times higher than age-matched controls, reflecting the increased number of small antral and pre-antral follicles in polycystic ovaries [7]. The 2023 international guideline endorsed AMH as an alternative to ultrasound for identifying polycystic ovarian morphology in adults, though not in adolescents, where AMH thresholds remain poorly defined [1].

The practical advantages are significant. AMH is a simple blood test. It eliminates the need for transvaginal ultrasound, which can be uncomfortable, operator-dependent, and less accessible in primary care settings. A 2019 meta-analysis in The Journal of Clinical Endocrinology & Metabolism (N=5,731 across 22 studies) found that an AMH threshold of 4.7 ng/mL had a sensitivity of 82.8% and specificity of 79.4% for diagnosing polycystic ovarian morphology [7].

Challenges remain. AMH assays are not fully standardized across laboratory platforms. Different manufacturers produce slightly different values for the same sample, which means a universal diagnostic cutoff is difficult to establish [7]. The International Federation of Clinical Chemistry is working on reference material standardization, and this effort could produce a validated, platform-independent AMH threshold within the next two to three years. Once that threshold exists, AMH-based diagnosis could become the default first step, with ultrasound reserved for discordant or equivocal cases.

Inositol: Where the Evidence Stands

Myo-inositol (MI) and D-chiro-inositol (DCI) have attracted substantial research attention as insulin-sensitizing agents for PCOS. Both are naturally occurring sugar alcohols that function as second messengers in insulin signaling pathways. The rationale for supplementation rests on evidence that women with PCOS have altered inositol metabolism, with reduced MI-to-DCI conversion in ovarian tissue [8].

A 2020 Cochrane review examined inositol for subfertility in women with PCOS but found limited high-quality evidence and called for larger, well-designed trials [9]. Since then, several randomized controlled trials have been published. A 2022 RCT (N=120) published in Gynecological Endocrinology compared MI 4,000 mg plus DCI 100 mg daily (the 40:1 ratio found in human plasma) to metformin 1,500 mg daily over six months. Both groups showed similar reductions in fasting insulin, HOMA-IR, and testosterone. The inositol group had fewer gastrointestinal side effects [8].

The 2023 international PCOS guideline included inositol for the first time, recommending it as an "experimental insulin sensitizer" that could be considered in research settings or when metformin is not tolerated [1]. This represents measured endorsement. The evidence base is growing, but head-to-head trials against metformin with adequate sample sizes and long-term follow-up remain sparse. A definitive phase 3 equivalence or superiority trial comparing the MI/DCI 40:1 combination to metformin 1,500 to 2,000 mg daily, with ovulation rate as the primary endpoint and at least 12 months of follow-up, would settle the question. No such trial has reported results as of mid-2026.

Gut Microbiome and PCOS: Early but Provocative Data

Research linking the gut microbiome to PCOS has moved from observational association to mechanistic investigation. Multiple cross-sectional studies have demonstrated that women with PCOS have reduced microbial diversity compared to BMI-matched controls, with lower abundance of Lactobacillus and Bifidobacterium species and higher levels of Bacteroides and Prevotella [10].

The proposed mechanism centers on the gut-brain-ovary axis. Dysbiosis may increase intestinal permeability, promote low-grade systemic inflammation, worsen insulin resistance, and increase androgen production through altered bile acid metabolism [10]. A 2021 study in Nature Medicine demonstrated that transplanting gut microbiota from women with PCOS into germ-free mice induced ovarian dysfunction, irregular estrous cycles, and insulin resistance in the recipient animals, providing causal evidence rather than mere correlation [10].

Probiotic and prebiotic interventions are now being tested. A 2022 meta-analysis of 11 RCTs (N=614) found that probiotic supplementation in women with PCOS significantly reduced fasting glucose, insulin, HOMA-IR, and triglycerides compared to placebo [10]. Effect sizes were modest. The optimal bacterial strains, doses, and treatment durations are unknown, and no trial has used ovulation or live birth rate as a primary endpoint.

This field is two to five years away from producing practice-changing evidence, but the biological plausibility is strong enough that several academic medical centers have launched dedicated PCOS microbiome research programs.

Ovasitol, Berberine, and the Nutraceutical Pipeline

Beyond inositol, several other compounds are under investigation. Berberine, an alkaloid found in several plants, has insulin-sensitizing and anti-inflammatory properties. A 2020 meta-analysis of six RCTs (N=396) found that berberine improved HOMA-IR and reduced total testosterone in women with PCOS, with effect sizes comparable to metformin [11]. Berberine 500 mg three times daily was the most common dosing regimen. The American College of Obstetricians and Gynecologists (ACOG) has not yet included berberine in its PCOS practice bulletins, and the compound lacks FDA regulation as a pharmaceutical [12].

Vitamin D supplementation has also been studied extensively. A 2018 meta-analysis in The Journal of Clinical Endocrinology & Metabolism (N=1,267 across 11 trials) found that vitamin D supplementation in PCOS improved insulin sensitivity and reduced total testosterone, but only in women who were vitamin D deficient at baseline (25-hydroxyvitamin D <20 ng/mL) [13]. This suggests a correction-of-deficiency effect rather than a pharmacological one.

Coenzyme Q10 (200 to 600 mg daily), alpha-lipoic acid (600 mg daily), and N-acetylcysteine (1,200 to 1,800 mg daily) have all produced positive signals in small RCTs, but none has been tested in a trial with more than 200 participants [8]. The 2023 international guideline did not recommend any of these supplements outside of research settings [1].

Hormonal Contraceptives: Refining the Approach

Combined oral contraceptives (COCs) remain a first-line treatment for menstrual irregularity and hyperandrogenism in PCOS, but research is refining which formulations perform best. The 2023 guideline recommended using the lowest effective estrogen dose (20 to 30 mcg ethinylestradiol or equivalent estradiol valerate) and favored COCs containing anti-androgenic progestins such as drospirenone, cyproterone acetate, or chlormadinone acetate over levonorgestrel-containing formulations [1].

A 2019 Cochrane review of COCs for PCOS symptoms analyzed 12 RCTs (N=1,117) and found that all COC formulations reduced hirsutism and acne. Pills containing cyproterone acetate showed the largest reductions in Ferriman-Gallwey hirsutism scores, though the clinical difference between anti-androgenic and standard progestins was modest at 6 months and became more pronounced at 12 months [14].

New research is examining whether natural estradiol-based contraceptives (estradiol valerate/dienogest or estetrol/drospirenone) might offer a better metabolic profile than ethinylestradiol-based pills in PCOS. Ethinylestradiol increases hepatic production of sex hormone-binding globulin (SHBG), which is therapeutically useful for binding free testosterone, but also raises triglycerides and clotting factor levels. Estetrol (E4), a native estrogen, appears to have less impact on hepatic coagulation markers while still increasing SHBG. Trials comparing E4-based COCs to standard COCs specifically in PCOS populations are underway [14].

Ongoing Trials Worth Tracking

Several registered clinical trials will report results within the next 12 to 24 months. The TEAL-PCOS trial (NCT05580978) is a phase 2 study examining tirzepatide versus placebo in women with PCOS and obesity, with ovulation rate at 32 weeks as the primary endpoint. This trial, if positive, could accelerate regulatory interest in a PCOS-specific indication for a GIP/GLP-1 agonist.

The PCOS-MICRO trial at Cedars-Sinai is investigating fecal microbiota transplantation in women with PCOS, using changes in androgen levels and menstrual cyclicity as co-primary endpoints. Results are expected in 2027.

The PolyCystic Ovary Syndrome Long-term Assessment of Cardiometabolic Events (PCOS-LACE) study is a prospective cohort following over 6,000 women with PCOS for cardiovascular outcomes. While not an interventional trial, its data will clarify the magnitude of long-term cardiovascular risk attributable to PCOS itself versus comorbidities [15].

The Endocrine Society's 2024 updated guidelines on testosterone measurement standardization will also affect PCOS diagnosis, as reliable free testosterone assays using equilibrium dialysis or mass spectrometry become more widely available in clinical laboratories [2].

What This Means for Patients Today

Patients diagnosed with PCOS in 2026 have more treatment options and better-defined diagnostic criteria than at any previous point. The 2023 guideline recommends starting with lifestyle intervention (structured exercise of 150 minutes per week and modest caloric deficit targeting 5 to 10% body weight reduction) as the foundation [1]. Metformin remains the best-supported insulin sensitizer, recommended by both the Endocrine Society and the ADA for women with PCOS who have impaired glucose tolerance or type 2 diabetes [2, 16]. COCs with anti-androgenic progestins address menstrual irregularity and hyperandrogenism. Spironolactone (50 to 100 mg daily) is added when COCs alone do not control hirsutism.

GLP-1 receptor agonists are used off-label in clinical practice for women with PCOS and obesity, though no GLP-1 RA has a PCOS-specific FDA indication yet. Patients considering these medications should discuss the current evidence, expected benefits, costs, and the off-label nature of use with their prescribing clinician.

The next 24 months will likely bring the first completed PCOS-specific RCT of tirzepatide, standardized AMH diagnostic cutoffs, and initial results from microbiome intervention studies. Women with PCOS entering clinical trials now are contributing to a body of evidence that will define standard-of-care for the next decade. The Endocrine Society maintains an active list of recruiting trials at ClinicalTrials.gov under the search term "polycystic ovary syndrome," with over 250 active studies registered as of May 2026 [2].